Literature DB >> 3686357

Lethal hyperparathyroid crisis: hazards of phosphate administration.

A M Vernava1, L W O'Neal, V Palermo.   

Abstract

Two patients with hypercalcemia crisis and parathyroid adenoma died as a result of pulmonary insufficiency. The administration of phosphate is believed to have contributed to the deaths, since the pulmonary problems appeared when the blood [Ca] X [PO4] product rose and extensive metastatic calcification was present in the pulmonary alveolar lining. The use of phosphates as calcium-lowering agents in hypercalcemia is discouraged, because phosphate appears to lower calcium levels only by intravascular precipitation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3686357

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  4 in total

1.  Metastatic calcifications and severe hypercalcemia in a patient with parathyroid carcinoma.

Authors:  P Valdivielso; J López-Sánchez; A Garrido; J J Sánchez-Carrillo
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

2.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

3.  Management of hyperparathyroid patients with grave hypercalcemia.

Authors:  L E Tisell; G Hedbäck; S Jansson; G Lindstedt; B F Zachrisson
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

4.  Acute respiratory distress syndrome driven by severe hypercalcemia and acute kidney injury: A case report and literature review of a rare, life-threatening complication.

Authors:  Haresh Selvaskandan; Katherine Hull; Rachel Gregory; Daniel Pan; Thrasos Macriyiannis; Jenny Briggs; Catherine Richards; Catherine Mason; Jorge Jesus-Silva; Ricky Bell
Journal:  Clin Nephrol Case Stud       Date:  2022-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.